Cited by 215Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorHallucinations in medical conditions

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

Open access

Halberstadt, Adam L, Koedood, Liselore, Powell, Susan B, Geyer, Mark A·2011·Journal of Psychopharmacology

DOI 10.1177/0269881110388326PMC PMC3531560

Open this paper in CoChat — free account

Abstract

Psilocin (4-hydroxy- N, N-dimethyltryptamine) is a hallucinogen that acts as an agonist at 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors. Psilocin is the active metabolite of psilocybin, a hallucinogen that is currently being investigated clinically as a potential therapeutic agent. In the present investigation, we used a combination of genetic and pharmacological approaches to identify the serotonin (5-HT) receptor subtypes responsible for mediating the effects of psilocin on head twitch response (HTR) and the behavioral pattern monitor (BPM) in C57BL/6J mice. We also compared the effects of psilocin with those of the putative 5-HT 2C receptor-selective agonist 1-methylpsilocin and the hallucinogen and non-selective serotonin receptor agonist 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT). Psilocin, 1-methylpsilocin, and 5-MeO-DMT induced the HTR, effects that were absent in mice lacking the 5-HT 2A receptor gene. When tested in the BPM, psilocin decreased locomotor activity, holepoking, and time spent in the center of the chamber, effects that were blocked by the selective 5-HT 1A antagonist WAY-100635 but were not altered by the selective 5-HT 2C antagonist SB 242,084 or by 5-HT 2A receptor gene deletion. 5-MeO-DMT produced similar effects when tested in the BPM, and the action of 5-MeO-DMT was significantly attenuated by WAY-100635. Psilocin and 5-MeO-DMT also decreased the linearity of locomotor paths, effects that were mediated by 5-HT 2C and 5-HT 1A receptors, respectively. In contrast to psilocin and 5-MeO-DMT, 1-methylpsilocin (0.6–9.6 mg/kg) was completely inactive in the BPM. These findings confirm that psilocin acts as an agonist at 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors in mice, whereas the behavioral effects of 1-methylpsilocin indicate that this compound is acting at 5-HT 2A sites but is inactive at the 5-HT 1A receptor. The fact that 1-methylpsilocin displays greater pharmacological selectivity than psilocin indicates that 1-methylpsilocin represents a potentially useful alternative to psilocybin for development as a potential therapeutic agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881110388326

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“In recent years, a number of studies have examined the effects of psilocybin in human volunteers (Carter et al., 2004, 2005b; Gouzoulis-Mayfrank et al., 1998, 1999; Griffiths et al., 2006; Umbricht et al., 2003; Vollenweider et al., 1997, 2007; Wittmann et al., 2007).”
Hallucinogens
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Self-citation
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki, I., Nobler, M. S., & Frazer, A. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21483-5 · Cited by 305
Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
A possible correlation between drug-induced hallucinations in man and a behavioural response in mice
CORNE, S. J., & Pickering, R. W. (1967) · Psychopharmacology · doi:10.1007/bf00401509 · Cited by 271

Show all 65 references

Research works printed but not linked: 3

Eivindvik K, 1989, Acta Pharm Nord, 1, 295
Grob CS, 2010, Arch Gen Psychiatry
Krebs-Thomson K, 1996, Behav Pharmacol, 7, 551

Sorted by citations

Psychedelics
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“385 Thus, to block the 5-HT 2A R can not produce the antidepressant effects of psilocybin, only induce the hallucinogenic-like behaviors in mice.”
Background
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 435
Self-citation
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“…twitches in response to mescaline, DOI, DOM, LSD, DMT, 5-MeO-DMT, psilocin, or 1-methylpsilocin (González-Maeso et al., 2007; Keiser et al., 2009; Halberstadt et al., 2011), although the response can be rescued by selectively restoring the 5-HT2A receptor gene to cortical regions (González-Maeso…”
BackgroundInfluentialSelf-citation
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F. D., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
Self-citation
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model
Canal, C. E., & Morgan, D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1333 · Cited by 234
Characterization of the head-twitch response induced by hallucinogens in mice
Halberstadt, A. L., & Geyer, M. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3006-z · Cited by 228
Self-citation
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovš, G., Krystal, J. H., Murray, J. D., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.12.027 · Cited by 188
Mushroom-Derived Indole Alkaloids
Homer, J. A., & Sperry, J. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00390 · Cited by 160
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny, T., Preller, K., Kraehenmann, R., & Vollenweider, F. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.005 · Cited by 116
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 125
The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 126
Effect of Hallucinogens on Unconditioned Behavior
Halberstadt, A. L., & Geyer, M. A. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_466 · Cited by 117
Self-citation
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response
Erkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 114
Investigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 103
Self-citation
Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
Four factors underlying mouse behavior in an open field
Tanaka, S., Young, J. W., Halberstadt, A. L., Masten, V. L., & Geyer, M. A. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.045 · Cited by 94
Self-citation
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor
Baladi, M. G., Forster, M. J., Gatch, M. B., Mailman, R. B., Hyman, D. L., Carter, L. P., & Janowsky, A. J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248120 · Cited by 92
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
Glatfelter, G. C., Pottie, E., Partilla, J. S., Sherwood, A. M., Kaylo, K. W., Pham, D. N. K., Naeem, M., Sammeta, V. R., DeBoer, S., Golen, J. A., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00177 · Cited by 95
Acute psilocybin enhances cognitive flexibility in rats
Pacheco, A. T., Olson, R. J., Garza, G., & Moghaddam, B. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01545-z · Cited by 94
Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
Tylš, F., Páleníček, T., Kadeřábek, L., Fujáková-Lipski, M., Kubešová, A., & Horáček, J. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000198 · Cited by 84
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 94
Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
N -Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues
Nichols, D. E., Sassano, M. F., Halberstadt, A. L., Klein, L. M., Brandt, S. D., Elliott, S. P., & Fiedler, W. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500292d · Cited by 80
Self-citation
Structural pharmacology and therapeutic potential of 5-methoxytryptamines
Warren, A. L., Lankri, D., Cunningham, M. J., Serrano, I. C., Parise, L. F., Kruegel, A. C., Duggan, P., Zilberg, G., Capper, M. J., Havel, V., et al. (2024) · Nature · doi:10.1038/s41586-024-07403-2 · Cited by 84
Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model
Canal, C. E., Booth, R. G., & Morgan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.007 · Cited by 69
Serotonergic hallucinogens as translational models relevant to schizophrenia
Halberstadt, A. L., & Geyer, M. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000722 · Cited by 72
Self-citation
Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice
Zhuk, O. V., Jasicka-Misiak, І., Poliwoda, A., Kazakova, A., Годован, В. В., Halama, M., & Wieczorek, P. P. (2015) · Toxins · doi:10.3390/toxins7041018 · Cited by 62
Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo
Revenga, M. D. L. F., Shin, J. M., Vohra, H., Hideshima, K. S., Schneck, M. B., Poklis, J. L., & González‐Maeso, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-49913-4 · Cited by 59
Potential Differences in Psychedelic Actions Based on Biological Sex
Shadani, S., Conn, K., Andrews, Z. B., & Foldi, C. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae083 · Cited by 62
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM‐775)
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J. V., Stratford, A., Klein, L. M., McCorvy, J. D., Nichols, D. E., et al. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2222 · Cited by 58
Self-citation
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 57
The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat
Rambousek, L., Páleníček, T., Valeš, K., & Stuchlík, A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00180 · Cited by 54
The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.049 · Cited by 50
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms
Conn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Lemus, M. B., Greaves, E., Homman‐Ludiye, J., Oldfield, B. J., & Foldi, C. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02575-9 · Cited by 58
Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding
Effinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G., & Herman, M. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02414-5 · Cited by 51
Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice
Halberstadt, A. L., Powell, S. B., & Geyer, M. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.014 · Cited by 52
Self-citation
Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MS n , and LC–HR–MS–MS
Michely, J. A., Helfer, A. G., Brandt, S. D., Meyer, M. R., & Maurer, H. H. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8955-0 · Cited by 49
Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action
Canal, C. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_107 · Cited by 50
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Fadahunsi, N., Lund, J. T., Breum, A. W., Mathiesen, C. V., Larsen, I. B., Knudsen, G. M., Klein, A. B., & Clemmensen, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02103-9 · Cited by 47
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs
Klein, L. M., Cozzi, N. V., Daley, P. F., Brandt, S. D., & Halberstadt, A. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.028 · Cited by 45
Self-citation
Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network
Halberstadt, A. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65264-x · Cited by 43
Self-citation
Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 49
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD)
Halberstadt, A. L., Chatha, M., Klein, A. K., McCorvy, J. D., Meyer, M. R., Wagmann, L., Stratford, A., & Brandt, S. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107856 · Cited by 38
Self-citation
Bioactive Alkaloids of Hallucinogenic Mushrooms
Wieczorek, P. P., Witkowska, D., Jasicka-Misiak, І., Poliwoda, A., Oterman, M., & Zielińska, K. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63462-7.00005-1 · Cited by 44
Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT1A receptor knockout mice: Implications for schizophrenia
van den Buuse, M., Ruimschotel, E., Martin, S., Risbrough, V. B., & Halberstadt, A. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.001 · Cited by 39
Self-citation
Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine
Halberstadt, A. L. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.01.005 · Cited by 35
Self-citation
Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models
van Enkhuizen, J., Geyer, M. A., Minassian, A., Perry, W., Henry, B. L., & Young, J. W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.008 · Cited by 32
Self-citation
The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors
Riga, M. S., Bortolozzi, A. A., Campa, L., Artigas, F., & Celada, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.016 · Cited by 33
Locomotor Profiling from Rodents to the Clinic and Back Again
Young, J. W., Minassian, A., & Geyer, M. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5015 · Cited by 33
Self-citation
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice
Takaba, R., Ibi, D., Yoshida, K., Hosomi, E., Kawase, R., Kitagawa, H., Goto, H., Achiwa, M., Mizutani, K., Maeda, K., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02778-x · Cited by 35
25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential
Custodio, R. J. P., Sayson, L. V., Botanas, C. J., Abiero, A., You, K. Y., Kim, M., Lee, H. J., Yoo, S. Y., Lee, K. W., Lee, Y. S., et al. (2019) · Addiction Biology · doi:10.1111/adb.12850 · Cited by 31
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history
Pearson, C., Siegel, J. S., & Gold, J. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120096 · Cited by 34
Mushroom Poisoning Cases in Dogs and Cats: Diagnosis and Treatment of Hepatotoxic, Neurotoxic, Gastroenterotoxic, Nephrotoxic, and Muscarinic Mushrooms
Puschner, B., & Wegenast, C. (2011) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2011.12.002 · Cited by 31
Dimethyltryptamine: Endogenous Role and Therapeutic Potential
Rodrigues, A. V., Almeida, F., & Vieira‐Coelho, M. A. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1602291 · Cited by 34
Methyl transfer in psilocybin biosynthesis
Hudspeth, J. D., Rogge, K., Dörner, S., Müll, M., Hoffmeister, D., Rupp, B., & Werten, S. (2024) · Nature Communications · doi:10.1038/s41467-024-46997-z · Cited by 28
Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 33
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 30
Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
Glatfelter, G. C., Naeem, M., Pham, D. N. K., Golen, J. A., Chadeayne, A. R., Manke, D. R., & Baumann, M. H. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00222 · Cited by 29
Criticality supports cross-frequency cortical-thalamic information transfer during conscious states
Toker, D., Müller, E. J., Miyamoto, H., Riga, M. S., Lladó-Pelfort, L., Yamakawa, K., Artigas, F., Shine, J. M., Hudson, A. E., Pouratian, N., et al. (2023) · eLife · doi:10.7554/elife.86547 · Cited by 28
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“Consistent with another new study (Hesselgrave et al., 2021), our results indicate that structural remodeling in the medial frontal cortex is undeterred by a moderate knockdown of 5-HT 2A receptor availability.”
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Dourron, H. M., Nichols, C. D., Simonsson, O., Bradley, M. K., Carhart-Harris, R. L., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06517-1 · Cited by 36
Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (“FLY”) and benzodifuran (“DragonFLY”) analogs
Halberstadt, A., Chatha, M., Stratford, A., Grill, M., & Brandt, S. D. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.037 · Cited by 24
Self-citation
Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors
Jiang, X.-L., Shen, H.-W., & Yu, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.013 · Cited by 26
Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile
González, J., Prieto, J. P., Rodríguez, P., Cavelli, M., Benedetto, L., Mondino, A., Pazos, M., Seoane, G. A., Carrera, I., Scorza, C., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00374 · Cited by 26
Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice
Halberstadt, A. L., Chatha, M., Chapman, S. J., & Brandt, S. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119826610 · Cited by 25
Self-citation
Serotonin and Serotonin Receptors in Hallucinogen Action
Halberstadt, A. L., & Nichols, D. E. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70103-x · Cited by 26
Self-citation
Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., Roberts, B., Sciortino, J. H., Gibbons, W. J., Friedberg, L. M., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16466 · Cited by 26
Theoretical and practical considerations behind the use of laboratory animals for the study of Tourette syndrome
Macrı̀, S., Onori, M. P., & Laviola, G. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.014 · Cited by 26
Do the therapeutic effects of psilocybin involve actions in the gut?
Reed, F. M., & Foldi, C. J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.12.007 · Cited by 26
Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.033 · Cited by 26
Effect of 5-HT2C receptor agonist and antagonist on chronic unpredictable stress (CUS) - Mediated anxiety and depression in adolescent Wistar albino rat: Implicating serotonin and mitochondrial ETC-I function in serotonergic neurotransmission
Wankhar, W., Syiem, D., Pakyntein, C. L., Thabah, D., & Sunn, S. E. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112780 · Cited by 22
Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
Puigseslloses, P., Nadal‐Gratacós, N., Ketsela, G., Weiss, N., Berzosa, X., Estrada‐Tejedor, R., Islam, M. N., Holy, M., Niello, M., Pubill, D., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02506-8 · Cited by 25
Hallucinogenic drugs and their potential for treating fear‐related disorders: Through the lens of fear extinction
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 21
Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG
Chen, Y., Liu, J., Yao, Y., Yan, H., & Su, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1021729 · Cited by 19
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 24
Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
Huang, J. Y., Pham, M. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891512 · Cited by 20
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 25
Effect of a hallucinogenic serotonin 5‐HT2A receptor agonist on visually guided, hippocampal‐dependent spatial cognition in C57BL/6J mice
Zhang, G., Cinalli, D. A., & Stackman, R. W. (2017) · Hippocampus · doi:10.1002/hipo.22712 · Cited by 19
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 19
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin
Gattuso, J. J., Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177304 · Cited by 18
Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation
Schmitz, G. P., Chiu, Y.-T., Foglesong, M. L., Magee, S. N., MacKinnon, M., König, G. M., Kostenis, E., Hsu, L.-M., Shih, Y.-Y. I., Roth, B. L., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03611-0 · Cited by 20
Immune-brain plasticity underpins stress and affective behaviors
Lee, J., & Wheeler, M. E. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.020 · Cited by 21
(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice
Rudin, D., McCorvy, J. D., Glatfelter, G. C., Luethi, D., Szöllősi, D., Ljubišić, T., Kavanagh, P. V., Dowling, G., Holy, M., Jäntsch, K., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01221-0 · Cited by 17
Self-citation
5-Methoxy-α-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex
Abiero, A., Botanas, C. J., Sayson, L. V., Custodio, R. J. P., de la Peña, J. B., Kim, M., Lee, H. J., Seo, J., Ryu, I. S., Chang, C. M., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.07.020 · Cited by 17
Automated Computer Software Assessment of 5-Hydroxytryptamine 2A Receptor-Mediated Head Twitch Responses from Video Recordings of Mice
Glatfelter, G. C., Chojnacki, M. R., McGriff, S. A., Wang, T., & Baumann, M. H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00237 · Cited by 18
Psilocybin as a novel treatment for chronic pain
Askey, T., Lasrado, R., Maiarù, M., & Stephens, G. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17420 · Cited by 18
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Analytical characterization of seventeen ring-substituted N,N-diallyltryptamines
Brandt, S. D., Kavanagh, P., Dowling, G., Talbot, B., Westphal, F., Meyer, M., Maurer, H., & Halberstadt, A. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1974 · Cited by 13
Self-citation
Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines
Kolaczynska, K. E., Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794254 · Cited by 15

Authors: Halberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A.
Affiliations: Department of Psychiatry, University of California, La Jolla, CA, USA.
Corresponding author: Geyer, Mark A
ORCID: Halberstadt, Adam L
Powell, Susan B
Geyer, Mark A
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2010-12-08
Volume: 25
Issue: 11
Pages: 1548-1561
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881110388326
PMC: PMC3531560
OpenAlex: W2107441654
Cited by: 213
References: 65
Citations by year: 2026: 24 · 2025: 32 · 2024: 31 · 2023: 20 · 2022: 18 · 2021: 8 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 5 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 8 · 2012: 4
FWCI: 5.96
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: University of California, San Diego
National Institute of Mental Health
National Institute on Drug Abuse (F32DA025412, R01DA002925)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Keywords: psilocin, psilocybin, 5-MeO-DMT, serotonin receptors, 5-HT1A receptor, 5-HT2A receptor, 5-HT2C receptor, head-twitch response, locomotor activity, WAY-100635, SB242084, receptor selectivity, hallucinogens
MeSH terms: Animals, Behavior, Hallucinogens, Male, Methoxydimethyltryptamines, Mice, Inbred C57BL, Motor Activity, Piperazines, Psilocybin, Pyridines, Receptors, Serotonin, Serotonin Antagonists, Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks